Akebia Therapeutics Sets New 12-Month High at $31.00 (AKBA)
Akebia Therapeutics (NASDAQ:AKBA)’s share price reached a new 52-week high on Friday , Analyst Ratings Net reports. The stock traded as high as $31.00 and last traded at $30.36, with a volume of 110,440 shares. The stock had previously closed at $27.28.
A number of research firms have recently commented on AKBA. Analysts at Zacks initiated coverage on shares of Akebia Therapeutics in a research note on Wednesday, April 23rd. They set a “hold” rating on the stock. Separately, analysts at Nomura reiterated a “buy” rating on shares of Akebia Therapeutics in a research note on Monday, April 14th. They now have a $39.00 price target on the stock. Finally, analysts at Nomura initiated coverage on shares of Akebia Therapeutics in a research note on Monday, April 14th. They set a “buy” rating and a $16.86 price target on the stock.
The stock has a 50-day moving average of $24.51 and a 200-day moving average of $23.22. The company’s market cap is $533.8 million.
Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.34. On average, analysts predict that Akebia Therapeutics will post $-2.04 earnings per share for the current fiscal year.
Akebia Therapeutics Inc is a United States-based biopharmaceutical company, which is focused on the development of small molecules for the treatment of anemia and vascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.